Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: Results of two pilot trials

Journal of Supportive Oncology

Volumn 6, Issue 1, 2008, Pages 27-32

  Bleicher, Jacob ^a,b   Bhaskara, Achala ^a,b   Huyck, Tim ^a,b   Constantino, Susan ^a,b   Bardia, Aditya ^a,b   Loprinzi, Charles L ^a,b   Silberstein, Peter T ^a,b  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANISETRON; HALOPERIDOL; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; LORAZEPAM; MESNA; ONDANSETRON; OXALIPLATIN; PACLITAXEL; PALONOSETRON; PREDNISONE; RITUXIMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ARTICLE; ASTROCYTOMA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON CANCER; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOLLICULAR LYMPHOMA; GEL; HODGKIN DISEASE; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MERKEL CELL TUMOR; METASTASIS POTENTIAL; OVARY CANCER; PANCREAS CANCER; PILOT STUDY; QUESTIONNAIRE; SEDATION;

ADMINISTRATION, CUTANEOUS; ADULT; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DIPHENHYDRAMINE; DRUG DELIVERY SYSTEMS; GELS; HALOPERIDOL; HUMANS; LORAZEPAM; NAUSEA; NEOPLASMS; PILOT PROJECTS; QUESTIONNAIRES; SKIN; VOMITING;

EID: 38949186751     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Kris MG, Gralla RJ, Tyson LB, et al. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine: results of consecutive trials in 255 patients. Cancer 1985;55:527-534.[3880660]
2. Kris MG, Gralla RJ, Clark RA, Tyson LB, Groshen S. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone:a double-blind,randomized trial. Cancer 1987;60:2816-2822.[3315176]
3. Kris MG, Hesketh PJ. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2005:13:85-96.[15565277]
4. Sridhar KS, Donnelly E. Combination antiemetics for cisplatin chemotherapy. Cancer 1988;61:1508-1517. [3280112]
5. Morrow GR, Hickok JT, Burish TG, Rosenthal SN. Frequency and clinical implications of delayed nausea and delayed emesis. Am J Clin Oncol 1996;19:199-203. [8610650]
6. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.Cancer 2004;100:2261-2268.[15139073]
7. Roila F, Del Favero A. Antiemetics revisited. Curr Opin Oncol 1997;9:321-326.[9251881]
8. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472-4478. [16983116]
9. O'Brien BJ, Rusthoven J, Rocchi A, et al. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. CMAJ 1993;149:296-302. [8339175]
10. Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004;15:526-536.[14998860]
11. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999;17:2971-2994.[10561376]
12. Loprinzi CL, Alberts SR, Christensen BJ, et al. History of the development of antiemetic guidelines at Mayo Clinic Rochester.Mayo Clin Proc 2000;75:303-309.[10725961]
13. Lindley C, Goodin S, McCune J, et al. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol 2005;28:270-276.[15923800]
14. Aranda Aguilar E, Constenla Figueiras M, Cortes-Funes H, et al. Clinical practice guidelines on antiemetics in oncology. Expert Rev Anticancer Ther 2005;5:963-972.[16336087]
15. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. American Society of Clinical Oncology. J Clin Oncol 2006;24:2932-2947.[16717289]
16. Italian Group For Antiemetic Research. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 2004;22:725-729.[14966097]
17. Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy. Med Lett Drugs Ther 2004;46:27-28
18. Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting:current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer 2005;41:199-205.
19. Abali H, Oyan B, Guler N. Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer. Chemotherapy 2005;51:280-285.[16103667]
20. Bregni M, Siena S, Di Nicola M, Bonadonna G, Gianni AM.Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. Eur J Cancer 1991;27:561-565.[1828962]
21. Josefson A, Kreuter M. Acupuncture to reduce nausea during chemotherapy treatment of rheumatic diseases. Rheumatology (Oxford) 2003;42:1149-1154. [12777644]
22. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323:16-21. [11440936]
23. Bruera E, Moyano JR, Sala R, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manage 2004;28:381-388.[15471656]
24. Glaus A, Knipping C, Morant R, et al. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 2004;12:708-715.[15278682]
25. López-Jimenéz J, Martín-Ballesteros E, Sureda A, et al. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 2006;91:84-91.[16434375]
26. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Antiemesis. V.I.2007. Available at: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed December 19, 2007.
27. Tolen L, McMath JA, Alt C, Weschules DJ, Knowlton CH, McPherson ML. Initial selection of antiemetics in end-of-life care: a retrospective analysis. Presented as a poster at the 2005 Annual Assembly of the American Academy of Hospice and Palliative Medicine and the Hospice and Palliative Nurses Association; January 19-23, 2005; New Orleans, LA. Abstract 731.
28. Weschules DJ. Tolerability of the compound ABHR in hospice patients. J Palliat Med 2008;8:1135-1143.[16351526]
29. Moon RB. ABHR gel in the treatment of nausea and vomiting in the hospice patient. Int J Pharm Compounding 2006;10:95-99.
30. Neidhart JA, Gagen MM, Wilson HE, Young DC. Comparative trial of the antiemetic effects of THC and haloperidol. J Clin Pharmacol 1981;21:38S-42S. [627183]
31. Snyder SH. Dopamine receptors, neuroleptics, and schizophrenia. Am J Psychiatry 1981;138:460-464. [6111227]
32. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update.Clin Pharmacokinet 1999;37:435-456. [10628896]
33. Garnett WR. Diphenhydramine. Am Pharm 1986;NS26:35-40.[3962845]
34. Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 1981;6:89-105.[6111408]
35. Maher J. Intravenous lorazepam to prevent nausea and vomiting associated with cancer chemotherapy. Lancet 1981;1:91-92.
36. Friedlander ML, Kearsley JH, Sims K, et al. Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy. Aust N Z J Med 1983;13:53-56.[6136266]
37. Davies A, Adena MA, Keks NA, Catts SV, Lambert T, Schweitzer I. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin Ther 1998;20:58-71.[9522104]